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Effects of oestradiol and vitamin B, on tryptophan 
metabolism in the rat: implications for the interpretation of the 
tryptophan load test for vitamin B, nutritional status 
BY DAVID A. BENDER 
Courtauld Institute of Biochemistry, The Middlesex Hospital Medical School, 
London W l P  7PN 
(Received 15 November 1982 - Accepted 24 January 1983) 
1. The effects of the administration of oestradiol and vitamin B, on tryptophan metabolism in the rat have 
been assessed by measurement of the release of 14C0, from [14C]tryptophan, in vivo, in order to determine whether, 
and to what extent, the abnormalities of tryptophan metabolism that are associated with oestrogen administration 
can be attributed to drug-induced vitamin B, deficiency or depletion. Two positional isomers of [14qtryptophan 
have been used; [ring-2JqC]tryptophan as an index of the activity of tryptophan oxygenase (L-tryptophan: oxygen 
oxidoreductase (decyclizing), EC 1 . 13.11 . 11) and [me~hylene-’~C]trytophan as an index of the activity of 
kynureninase (L-kynurenine hydrolase, EC 3.7.1 .3). 
2. The administration of 500 pg oestradiol/kg body-weight led to a reduction in the release of 14C0, from both 
positional isomers of tryptophan, suggesting that the activities of both tryptophan oxygenase and kynureninase 
are reduced following oestrogen treatment. The kinetics of the release of 14C0, from [methylene-14C]tryptophan 
after the administration of oestradiol were compatible with competitive inhibition of kynureninase by oestradiol 
or a metabolite. 
3. The administration of 10 mg pyridoxine hydrochloride/kg body-weight also reduced the production of l4COZ 
from both positional isomers of [14C]tryptophan, suggesting some toxicity of such a high dose of the vitamin. 
4. In animals which had received the supplementary dose of vitamin B,, the administration of oestradiol led 
to further reduction in the production of 14C0, from [ring-2-14C]tryptophan, suggesting a further reduction in 
the activity of tryptophan oxygenase, and an increase in the production of 14C0, from [methylene-I4C]tryptophan, 
but with a delay in the peak of production. 
5. These results confirm that there is no  induction of tryptophan oxygenase by oestradiol, but rather reduced 
activity of the enzyme after the administration of a relatively high dose of the hormone. They also confirm that 
the inhibition of kynureninase by oestrogen metabolites that has been reported previously in partially-purified 
enzyme preparations also occurs in vivo. 
6. It is suggested that the abnormal results of the tryptophan load test that have been reported in women 
receiving oestrogens, and which have been interpreted as indicating some extent of drug-induced vitamin B, 
deficiency, can be accounted for by the inhibition of tryptophan metabolism by oestrogens or their metabolites. 
Therefore it seems likely that the practice of administering supplements of vitamin B, to women receiving 
oestrogens may not be appropriate, and indeed may exacerbate the changes in tryptophan metabolism that result 
from the administration of oestrogens. The tryptophan load test would appear to be unreliable as an index of 
vitamin B, nutritional status in women receiving oestrogens. 
The tryptophan load test for vitamin B, nutritional status depends on the fact that 
kynureninase (L-kynurenine hydrolase, EC 3 . 7 . 1  .3)  is a pyridoxal phosphate-dependent 
enzyme and, in vitamin B, deficiency, the activity of the enzyme falls as its cofactor is 
depleted (Knox, 1953). This results in a considerable accumulation in the liver of kynurenine 
and hydroxykynurenine, the substrates of kynureninase, and an increase in the formation 
and excretion of kynurenic and xanthurenic acids after the administration of a loading dose 
of tryptophan. The excretion of these metabolites after the administration of a loading dose 
of tryptophan is considered to reflect the state of the body’s reserves of vitamin B, (Coursin, 
1964; Price et al. 1965). 
A number of studies have demonstrated abnormalities of tryptophan metabolism which 
appear to be the result of vitamin B, deficiency or depletion, in women receiving oestrogens 
as oral contraceptives or menopausal hormone-replacement therapy (Rose & Braidman, 
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1971; Rose et al. 1972; Aylward, 1976). As a result of these studies, a number of 
preparations have been marketed for sale without prescription, providing relatively large 
amounts of vitamin B, (of the order of 20-50 mg/d, some ten to twenty times greater than 
the US recommended daily allowance for vitamin B,) to overcome the supposed oestrogen- 
induced vitamin deficiency, and hence some of the unwanted side-effects of oestrogen 
administration. It is doubtful whether such supplementation with large amounts of vitamin 
B, is either appropriate or desirable. Doses of the order of 20 mg of the vitamin/d are 
required to correct the abnormalities of tryptophan metabolism in women receiving 
oestrogens (Luhby et af. 1971) but studies that have assessed vitamin B, nutritional status 
by metabolic criteria other than the ability to metabolize a test dose of tryptophan, have 
shown no impairment of vitamin B,-dependent metabolism as a result of oestrogen 
administration (Brown et at. 1975; Leklem et al. 1975). 
Previous studies from this laboratory have suggested that the effects of oestrogen 
administration on tryptophan metabolism are not due to vitamin B, depletion, but can be 
accounted for by inhibition of kynureninase by oestrogen metabolites (Bender & Wynick, 
1981). Bender et al. (1982) showed that after chronic administration of oestrogens to rats 
there were changes in tryptophan metabolism that would be compatible either with such 
simple inhibition or with depletion of tissue reserves of the vitamin, but were unable to 
demonstrate any effect of oestrogen administration on blood or tissue concentrations of 
pyridoxal phosphate, or the urinary excretion of the principal metabolite of the vitamin, 
4-pyridoxic acid. They concluded that oestrogens do not deplete vitamin B,. 
The present study was undertaken in order to determine whether the inhibition of 
kynureninase by oestrogen metabolites that has been demonstrated using a partially-purified 
preparation of the enzyme (Bender & Wynick, 1981) is also important in vivo in response 
to the administration of oestrogens, and to confirm the finding that oestrogens do not induce 
new synthesis of tryptophan oxygenase (L-tryptophan : oxygen oxidoreductase (decyclizing), 
EC 1 .13.11.11) (Bender et af. 1983). The activities of tryptophan oxygenase and kynur- 
eninase were determined in vivo by measurement of the release of 14C0, after the 
administration to rats of either [rir~g-2-'~C]tryptophan (for tryptophan oxygenase activity) 
or [rnethyler~e-'~C]tryptophan (for kynureninase activity). The pathway involved is shown 
in Fig. 1. The results confirm that oestrogens do not induce tryptophan oxygenase, but 
rather lead to a slight reduction in the activity of this enzyme (Bender et al. 1983), and also 
that there is inhibition of kynureninase in vivo following the administration of oestradiol. 
It therefore seems unlikely that the abnormalities of tryptophan metabolism that have been 
observed in women receiving oestrogens are the result of drug-induced vitamin B, depletion, 
and supplementation of such women with the vitamin would appear to be inappropriate. 
METHODS 
Female Wistar rats weighing 195-210 g, bred in the Courtauld Institute of Biochemistry, 
were used. They were allowed free access to standard animal house diet (Diet 86; E. Dixon 
& Sons, Ware, Herts) at all times, apart from the 4 h period during which exhaled 14C0, 
was collected. 
On the first day of each study, each animal received an intraperitoneal injection of 1 ml 
ethanol-saline (0.15 M-sodium chloride; 50 ml/l) at 11.30 hours and then the radioactive 
material, dissolved in 1 ml saline, at 12.30 hours. On the second day of each study the same 
animals received an intraperitoneal injection of 500 pg oestradiol/kg body-weight in 1 ml 
ethanol-saline (50 ml/l) and the same radioactive tracer as the previous day, again at 12.30 
hours. Animals treated with vitamin B, received an intraperitoneal injection of 10 mg 
pyridoxine hydrochloride/kg body-weight, dissolved in 1 ml saline, at 16.30 hours the day 
before each experiment with radioactive material. For studies with [14C]tryptophan, animals 
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Fig. 1 .  The oxidative metabolism of tryptophan, showing the production of ''C-labelled carbon dioxide 
from (O), ~-[ring-2-K]tryptophan and (O), ~-[rnethylene-'~C]tryptophan. 
received 50 mg L-tryptophan/kg body-weight, together with a tracer dose of either 
~-[ring-2-l~C]tryptophan (Commissariat d'Energie Atomique, Gif-sur-Yvette, France) or 
~-[methylene-~~C]tryptophan (Amersham International, Amersham, Bucks) at a specific 
activity of 0.66 mCi/mmol. For studies with [l*C]formate and ~-[U-l~C]alanine (both from 
Amersham International) animals received 0.7 pCi of the radioactive material/kg body- 
weight, undiluted by any additional non-radioactive carrier. Thus, the metabolism of the 
radioactive material was assessed in the same animal before and after the administration 
of oestradiol; separate groups of rats were used for each of the four radioactive materials, 
and separate groups for the experiments in which the animals were pretreated with vitamin 
Immediately after the injection of radioactive material, animals were placed individually 
B,. 
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in sealed glass vessels through which moistened air was passed from a small compressor. 
Air leaving each vessel was bubbled through 2ml of a solution of Hyamine hydroxide 
solution (50 g/1 methanol-propan-2-01 (1 : 1, v/v)) to absorb CO,. Every 10 rnin the 
compressor was stopped for about 1 rnin and the solution of Hyamine hydroxide was 
replaced. The collection of 14C0, was continued for 4 h after the administration of 
[14C]tryptophan and for 3 h after [14C]fomate or alanine. The solution of Hyamine 
hydroxide was washed into scintillation-counter vials with a total of 10 ml of a solution 
of PPO (3 g/l) and POPOP (0.3 g/l) in toluene; radioactivity was measured using a 
Beckman LS 7500 liquid-scintillation counter equipped with automatic quench correction. 
14C0, production in each 10 min interval (shown in Figs. 2 and 3) was plotted and lines 
drawn by inspection. Values of the first-order rate-constant for the decay of 14C0, 
production (k) and the half-time of the decay were calculated from the gradient of the linear 
plot of log (radioactivity) v. time; this gradient was calculated by unweighted least squares 
regression. 
For the studies of urinary excretion of tryptophan metabolites, rats were housed 
individually in stainless-steel metabolism cages (Acme Metal Co. Inc., Chicago, Ill, USA). 
On the first day of the experiment, each animal received an intraperitoneal injection of 50 mg 
L-tryptophan/kg body-weight, dissolved in 5 ml saline, at 09.00 hours. Urine was collected 
over the next 7 h. During this time the animals had free access to water, but not food. At 
16.00 hours, each animal received an intraperitoneal injection of 10 mg pyridoxine 
hydrochloride/kg body-weight in 1 ml saline; the injection of tryptophan and collection of 
urine for 7 h from 09.00 hours were repeated the next day. Overnight, all animals had free 
access to stock diet and water. Urine samples were diluted to 20 ml with water and were 
stored at - 20' until they were required for analysis. 
N1-methyl nicotinamide was measured by the small-scale modification of the alkali-ketone 
fluorescence method of Carpenter & Kodicek (1950) that has been described previously 
(Bender, 1980 b). Xanthurenic and kynurenic acids and kynurenine were separated by 
ion-exchange chromatography on small columns of Dowex 50 W (H+) resin (Satoh & Price, 
1958); the two acids were determined fluorimetrically (Satoh & Price, 1958) and kynurenine 
colorimetrically after diazotization and coupling to naphthylene ethylene diamine (Joseph 
& Risby, 1975). 3-Hydroxykynurenine was measured fluorimetrically by the method of 
Watanabe et al. (1970). 
Methyl pyridone carboxamide was measured colorimetrically after conversion to the 
amine by means of the Konig reaction, diazotization and coupling to naphthylene ethylene 
diamine by the following modification of the method of Holman (1954). Potentially- 
interfering ionized compounds in urine were removed by mixing 5 ml of the diluted urine 
sample with 500 mg finely-powdered Zerolit DMF mixed-bed ion-exchange resin; after 1 h 
the resin was removed by centrifugation (2000 g for 15 min). This procedure was considerably 
simpler than the method described by Price (1954) using a column of alternating layers of 
anion- and cation-exchange resins; the recovery of authentic methyl pyridone carboxamide 
through the resin treatment was routinely between 98-100%. Portions of the deionized urine 
(1 ml) were mixed with 250 pl of a freshly-prepared solution of alkaline sodium hypobromite 
(1 ml of a solution of 125 g bromine and 144 g potassium bromide/l in 10 ml of0.25 M-sodium 
hydroxide), and was allowed to stand in the dark at room temperature for 5 min. This was 
then mixed with 250 pl of a solution of 5 g phenol/l water, and heated to 105' for 20 min 
in screw top vials. After cooling, samples were mixed with 250 p16 M-hydrochloric acid and 
cooled in ice for 20 min, followed by the addition at 5 rnin intervals of 200 p12.5 g sodium 
nitrite/l water, 200 pl ammonium sulphamate (100 g/l water) and 200 pl naphthylene 
ethylene diamine (10 g/1 ethanol-water (950 ml/l)). The solutions of NaNO, and naph- 
thylene ethylene diamine were prepared freshly for each batch of analyses. After standing at 
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Fig. 2. The effects of oestradiol(500 ,ug/kg body-weight) on the production of 14C-labelled carbon dioxide 
from ~-[ring-Z-'~C]tryptophan and [14C]formate in (a, b) control animals and (c, d) animals pretreated 
with 10 mg pyridoxine hydrochloride/kg body-weight. (a), Ethanol-saline control; (O), oestradiol in 
ethanol-saline. Points are mean values with their standard errors, represented by vertical bars, for three 
or six animals per group, as shown in Table 1. 
room temperature for 60 min the absorbance of the product was measured at 590 nm. 
Authentic methyl pyridone carboxamide for use as a standard was synthesized by the 
method of Holman & Wiegand (1948). 
RESULTS 
As can be seen from Fig. 2 and Table 1, the administration of 50Opg oestradiol/kg 
body-weight led to a reduction in the production of l4Co, from [ring-2-14C]tryptophan, and 
a significant fall in the value of k,  the first-order rate-constant for the decay phase of the 
curve of W O ,  production. A similar effect of oestradiol was observed whether or not the 
animals had been treated with 10 mg vitamin B, the day before the administration of 
[14C]tryptophan. The administration of vitamin B, led to a considerable reduction in the 
production of W O ,  from [ring-2-14C]tryptophan. 
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Oestradiol and tryptophan metabolism 
L- [ rne th~ /ene- '~C]  tryptophan L - [ U - ' ~ C ]  alanine 
39 
Period after injection (min) 
Fig. 3. The effects of oestradiol(500 pg/kg body-weight) on the production of 14C-labelled carbon dioxide 
from ~-[rnethylene-l~C]tryptophan d ~-~-'~C]alanine in (a, 6) control animals and (c, d) animals 
pretreated with 1.0 mg pyridoxine hydrochloride/kg body-weight. (O), Ethanol-saline control; (o), 
oestradiol in ethanol-saline. Points are mean values with their standard errors, represented by vertical 
bars, for three or six animals per group, as shown in Table 1. 
Neither vitamin B, nor oestradiol alone had any effect on the production of 14C0, from 
[14C]formate. However, in animals which had been pretreated with vitamin B,, the 
administration of oestradiol led to a lower total recovery of 14C0, from [14C]formate and 
a lower peak of 14C0, production, but a higher value of k .  
Fig. 3 shows the production of 14C0, from [me~hylene-~~CItryptophan and [U-14C]alanine. 
There was no significant effect of oestradiol on the total recovery of 14C0, from 
[me~hyZene-~~CItryptophan, or the peak height, but there was a considerable delay in the 
time of the peak of 14C0, production. This was apparent whether the animals had received 
vitamin B, or not, and was associated with a significant reduction in the value of k.  The 
administration of vitamin B, also led to a delay in the production of 14C0, from 
[methylene-14C]tryptophan and a reduction in the value of k.  
Oestradiol had no significant effect on the production of 14C0, from [U-14C]alanine in 
animals that had not received vitamin B,. Administration of the vitamin led to a reduction 
in the production of 14C0, and an increase in the value of k ;  the administration of 
oestradiol after vitamin B, pretreatment led to a further reduction in the total production 
of 14C0, from [Wlalanine, and a fall in the value of k .  
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Table 2. The efects of pyridoxine hydrochloride (vitamin B,) on the urinary excretion of 
tryptophan metabolites over 7 h after the intraperitoneal injection of 50 mg L-tryptophanlkg 
body-weight to female rats weighing 200 -t- 5 g 
(Mean values with their standard errors for six animals per group) 
Treatment. . . 
After 10 mg pyridoxine 
HCl/kg body-weight 
Control at -17h 
Metabolite Mean SEM Mean SEM 
Kynurenine @mol) 130 9 1 24 1 1  
3-Hydroxykynurenine (pmol) 70 7 88 9 
Kynurenic acid (mmol) 1.5 0.2 1 .1  0.1 
Xanthurenic acid (mmol) 0.67 0.03 0.64 0,04 
WMethyl nicotinamide @mol) 1.52 0.27 0.83** 0.093 
Methyl pyridone carboxamide (pmol) 0.45 0.036 0.30** 0.035 
Significance of differences from control (by t test): ** 0.05 >, P >, 0,001. 
Table 2 shows the urinary excretion of tryptophan metabolites by rats over a 7 h period 
after administration of 50 mg L-tryptophanlkg body-weight, before and 17 h after receiving 
10 mg pyridoxine hydrochloride/kg body-weight. Vitamin B, led to a significant reduction 
in the excretion of both N1-methyl nicotamide and methyl pyridone carboxamide, but had 
no significant effect on the excretion of kynurenine, hydroxykynurenine, kynurenic acid or 
xanthurenic acid. 
DISCUSSION 
The production of 14C02 is not a direct consequence of the metabolism of either of the 
positional isomers of [14C]tryptophan that have been used in this study. With [ring- 
2-14C]tryptophan the result of the activities of tryptophan oxygenase and formylkynurenine 
formamidase (EC 3.5 . 1 .9) is the production of [14C]formate. With [merhylene- 
l4CItryptophan the immediate product of kynureninase action is [14C]alanine, which must 
undergo transamination to pyruvate and then oxidation by way of the citric acid cycle before 
14C02 is released. This means that with either substrate the effects of experimental 
treatments on metabolic reactions occurring later than the enzymes under consideration may 
affect the results. The effects of oestradiol and vitamin B, on the metabolism of [14C]formate 
and [14C]alanine have therefore been assessed; the results eliminate this possible artefact. 
These results show that even the relatively high dose of oestradiol used in the present 
study (500 pg/kg body-weight) does not cause induction of tryptophan oxygenase, an 
effect that would be expected to increase the rate of production of 14C0, from [ring- 
2-14C]tryptophan. Induction of tryptophan oxygenase by oestradiol was reported by 
Patnaik & Sarangai (1980), but Bender et al. (1983) were unable to reproduce their findings 
and suggested that what they had observed was an artifact due to changes in the recovery 
of kynurenine (the product of tryptophan oxygenase action) as a result of inhibition of 
kynureninase by oestrogen metabolites. Leonard & Hamburger (1974) suggested that in vivo 
there might be some increase in the activity of tryptophan oxygenase after oestrogen 
treatment as a result of increased synthesis of haem, and hence increased saturation of the 
apo-enzyme with its cofactor. No such effect has been observed in the present study. The 
present results confirm the previous observation (Bender et al. 1983) that after the 
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administration of oestrogens there is a slight reduction in the activity of tryptophan 
oxygenase. 
Bender & Wynick (1981) showed that oestrone sulphate and glucuronide were competitive 
inhibitors of kynureninase. They suggested that if such inhibition also occurred in vivo, as 
a result of the administration of oestrogens, it would explain the abnormalities of 
tryptophan metabolism that have been observed in women receiving oestrogens (Rose & 
Braidman, 1971; Rose et al. 1972; Aylward, 1976). The present results show that such 
inhibition of kynureninase does indeed result from the administration of oestrogens and 
is not ameliorated by the administration of vitamin B,. The results are compatible with a 
mechanism of inhibition that is competitive with respect to the substrate; a lower value of 
the rate constant (k)  after the administration of oestradiol and a delay in the time at which 
the peak of production of '*CO, is achieved, although with eventual attainment of the same 
peak height as before the administration of oestradiol. 
The inhibition of tryptophan metabolism by the administration of a relatively high dose 
of vitamin B, (10 mg/kg body-weight) seems to be the result of an effect at the level of 
tryptophan oxygenase. No satisfactory explanation can be advanced for this; the enzyme 
is not known to be pyridoxal phosphate-dependent, although it is inhibited by a number 
of hydrazine derivatives that form biologically inactive adducts with the vitamin (Young 
et al. 1978; Bender, 1980~). The administration of vitamin B, does not seem to affect the 
activity of kynureninase, as determined by the production of 14C0, from [methylene- 
14C]tryptophan, beyond such inhibition of production of 14C0, as can be accounted for 
by the reduced activity of tryptophan oxygenase. Table 2 shows that there was no change 
in the urinary excretion of kynurenine, hydroxykynurenine, kynurenic or xanthurenic acids 
after the administration of vitamin B,; inhibition of kynureninase would be expected to 
lead to an increase in the excretion of all of these metabolites. There was, however, a 
significant reduction in the excretion of two metabolites of the nicotinamide nucleotides, 
N1-methyl nicotinamide and methyl pyridone carboxamide, after the administration of 
vitamin B,. This presumably reflects a lower rate of synthesis of the nucleotides because 
of the lower rate of entry of tryptophan into the oxidative pathway. Such an effect may 
be clinically important in man; Serdaru et al. (1981) have reported the development of a 
pellagra-like neurological condition in two alcoholic patients treated with very large 
amounts of vitamins B, and B,. In the one patient in whom it was tried, the addition of 
nicotinamide to the parenteral vitamin mixture led to recovery. 
Previous studies from this laboratory (Bender & Wynick, 1981 ; Bender et al. 1982) have 
suggested that the abnormalities of tryptophan metabolism that have been reported in 
women receiving oestrogens (Rose & Braidman, 1971 ; Rose et al. 1972; Aylward, 1976) 
are not the result of oestrogen-induced vitamin B, deficiency or depletion, but rather the 
result of direct inhibition of tryptophan metabolism by oestrogens or their metabolites. The 
results of the present study confirm this, and suggest that the administration of relatively 
large supplements of vitamin B, may not be an appropriate treatment for the side-effects 
of oestrogens used as contraceptives or as menopausal hormone-replacement therapy. 
Indeed, the inhibition of tryptophan metabolism by the administration of large amounts 
of the vitamin demonstrated here suggests that such supplementation may be undesirable. 
Coon & Nagler (1969) showed that in patients suffering from a variety of diseases affecting 
the secretion of steroid hormones, and even under conditions of increased secretion of 
glucocorticoids as a result of the stress of severe illness, the tryptophan load test gave 
misleading results, indicative of vitamin B, deficiency, as a result of changes in tryptophan 
metabolism caused by changes in hormone status, although other indices of vitamin B, 
status were normal. The present study, and previous studies from this laboratory (Bender 
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& Wynick, 1981; Bender et al. 1982) suggest that in women receiving oestrogens as 
contraceptives or as menopausal hormone-replacement therapy the tryptophan load test 
may similarly be unreliable as an index of vitamin B, nutritional status. 
This study was supported by a grant from the Medical Research Council. 
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